Atreca Inc BCEL:NASDAQ

Earnings Announcement Next Earnings date is expected on 08/11/2020
Last Price$13.05NASDAQ Previous Close - Last Trade as of 3:59PM ET 8/03/20

Today's Change+0.10(0.77%)
Bid (Size)$10.07 (4)
Ask (Size)$15.11 (1)
Day Low / High$12.80 - 13.21
Volume495.8 K
 

View Miscellaneous Commercial Services IndustryPeer Comparison as of 08/03/2020

 

Atreca Inc ( NASDAQ )

Price: $13.05
Change: +0.10 (0.77%)
Volume: 495.8 K
3:59PM ET 8/03/2020
 
 

SP Plus Corp ( NASDAQ )

Price: $16.31
Change: +0.42 (2.64%)
Volume: 199.0 K
3:59PM ET 8/03/2020
 
 

Newtek Business Services Corp ( NASDAQ )

Price: $19.33
Change: +0.60 (3.20%)
Volume: 214.5 K
4:00PM ET 8/03/2020
 
 

Hackett Group Inc ( NASDAQ )

Price: $13.67
Change: -0.12 (0.91%)
Volume: 63.3 K
3:59PM ET 8/03/2020
 
 

Kimball Electronics Inc ( NASDAQ )

Price: $13.29
Change: +0.01 (0.08%)
Volume: 59.1 K
4:00PM ET 8/03/2020
 

Read more news Recent News

Atreca Prices Stock Offering at $16 Per Share
11:52AM ET 7/16/2020 MT Newswires

Atreca (BCEL) on Thursday priced a public offering of about 7 million of its Class A common shares and 781,250 of its Class B common shares at $16 per...

Atreca Proposes Upcoming Stock Sale, Shares Sink 5% in Late Trade
4:09PM ET 7/15/2020 MT Newswires

Atreca (BCEL) was down 5% in extended trading after the biopharmaceuticals company late Wednesday disclosed plans for a public offering of its Class A...

Atreca Joins Hands With Xencor to Develop, Commercialize Antibodies With Potential to Help Kill Tumor Cells
8:38AM ET 7/08/2020 MT Newswires

Atreca (BCEL) and Xencor (XNCR) announced early Wednesday a collaboration and license agreement to research, develop and commercialize T cell-engaging...

Analyst Actions: Canaccord Genuity Lifts Atreca's Price Target to $33 From $23, Keeps at Buy
11:32AM ET 7/01/2020 MT Newswires

Atreca (BCEL) has an average buy rating among analysts, with an average price target of $28. (MT Newswires covers equity, commodity and economic research...

Company Profile

Business DescriptionAtreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in South San Francisco, CA. View company web site for more details
Address450 E Jamie Court
South San Francisco, California 94080
Phone+1.650.595.2595
Number of Employees85
President, Chief Executive Officer & DirectorJohn A. Orwin
Chief Financial OfficerHerbert C. Cross
Chief Technology OfficerGuy Cavet
Senior Vice President-ResearchDaniel Emerling

Company Highlights

Price Open$13.14
Previous Close$13.05
52 Week Range$9.51 - 29.35
Market Capitalization$289.7 M
Shares Outstanding22.2 M
SectorCommercial Services
IndustryMiscellaneous Commercial Services
Next Earnings Announcement08/11/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$5.67
Beta vs. S&P 500N/A
Revenue$961.0 K
Net Profit Margin-3,378.32%
Return on Equity-38.07%

Analyst Ratings as of 05/15/2020

Buy
8
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset